Keyphrases
Malignancy
100%
CD19
100%
Mouse Model
100%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
CD19+
100%
Constitutively Active
100%
CAR19
33%
T Cells
25%
B Cells
25%
Weight Loss
16%
T Cell Activation
16%
B-cell Lymphoma
16%
Neoepitope
16%
Clinical Score
16%
Transgenic
8%
Transgenic Mouse Model
8%
Syngeneic
8%
C57BL
8%
Cyclophosphamide
8%
Reconstitution
8%
Low Incidence
8%
B-cell Malignancies
8%
Chimeric Antigen Receptor T-cell Therapy
8%
Tumor Therapy
8%
Peripheral Blood Lymphocytes
8%
Fab Fragment
8%
Improved Survival
8%
Cell Engraftment
8%
Tumor Burden
8%
Congenic
8%
Low Severity
8%
Hemizygous
8%
B6 Mice
8%
Specific Peptide
8%
B-cell Depletion
8%
Immune-competent
8%
Malignant B Cells
8%
Single-chain Fv Fragment
8%
Acute Morbidity
8%
Chronic Morbidity
8%
Loss Score
8%
Fragment Specific
8%
Immunology and Microbiology
Mouse Model
100%
CD19
100%
Chimeric Antigen Receptor T-Cell
100%
B Cell
57%
T Cell
21%
Engraftment
7%
Peripheral Blood Lymphocyte
7%
Chimeric Antigen Receptor T-Cell Therapy
7%
Cell Function
7%
Syngenic
7%
Immunity
7%
Transgenic Mouse
7%
Chimeric Antigen Receptor
7%
Transgenics
7%
Cell Activity
7%
Immunoglobulin F(ab) Fragment
7%
C57BL 6 Mouse
7%
Tumor Volume
7%
Target Cell
7%
Single-Chain Variable Fragment
7%
Cyclophosphamide
7%
Immunology
7%
Medicine and Dentistry
Cancer
100%
Chimeric Antigen Receptor T-Cell
100%
B Cell
54%
T Cell
27%
B-Cell Lymphoma
18%
Cell Function
9%
Cancer Therapy
9%
Transgenic Mouse
9%
Neoplasm
9%
Engraftment
9%
Immunity
9%
Cyclophosphamide
9%
C57BL/6
9%
Chimeric Antigen Receptor
9%
Side Effect
9%
Cell Activity
9%
Immunoglobulin F(ab) Fragment
9%
Target Cell
9%
Single Chain Fragment Variable Antibody
9%
Chimeric Antigen Receptor T-Cell Immunotherapy
9%
Lymphocyte
9%
Pharmacology, Toxicology and Pharmaceutical Science
Mouse Model
100%
Chimeric Antigen Receptor
100%
B Cell Lymphoma
33%
Neoplasm
33%
Transgenic Mouse
16%
C57BL 6 Mouse
16%
Cyclophosphamide
16%
Side Effect
16%
Immunoglobulin F(ab) Fragment
16%
Single Chain Fragment Variable Antibody
16%